Nanotechnology Revolutionizes Epigenetic Cancer Therapy with Precision Delivery and Sustained Release of DNA Methylation Modulators

Strategic Insights -

Researchers at Integral University in Lucknow, India have made significant advancements in cancer gene therapy by harnessing the power of nanotechnology. According to a recent study published in the Yale Journal of Biology and Medicine, aberrant DNA methylation is a key contributor to cancer, silencing tumor suppressor genes and facilitating tumor growth. DNA methyltransferase inhibitors (DNMTis), such as 5-azacytidine (5-AZA) and decitabine (DAC), can potentially mitigate these consequences and revive gene expression. However, their therapeutic effectiveness is hindered by factors like poor bioavailability, swift degradation, and unintended toxicity.

The researchers have explored various types of nanoformulations for DNMTi delivery, including PLGA nanoparticles, liposomes, solid lipid nanoparticles (SLNs), bentonite-based nanoparticles, gold nanoparticles (AuNPs), amphiphilic prodrugs, PEGylated nanoparticles, bionic nanoparticles, gelatinase-sensitive nanoparticles, and chitosan-based pH-responsive systems. This research emphasizes the integration of epigenetic therapies and nanotechnology in oncology, focusing on the creation of nanocarriers for precise delivery of methylation modulators and new formulations for prolonged drug release.

Key Takeaways:

  • The study highlights the potential of nanotechnology to revolutionize epigenetic cancer therapy, offering new hope for improved patient outcomes in precision oncology.
  • Aberrant DNA methylation is a key contributor to cancer, silencing tumor suppressor genes and facilitating tumor growth.
  • DNA methyltransferase inhibitors (DNMTis) can potentially mitigate these consequences and revive gene expression.
  • The researchers have explored various types of nanoformulations for DNMTi delivery, including PLGA nanoparticles, liposomes, and gold nanoparticles.
  • Nanocarriers can be developed for precise delivery of methylation modulators and prolonged drug release.
  • The study emphasizes the integration of epigenetic therapies and nanotechnology in oncology.
  • Anas Islam, Usama Ahmad, Mohd Muazzam Khan, and Juber Akhtar were among the researchers who contributed to this study.

Statistics:

  • 5-azacytidine (5-AZA) and decitabine (DAC) are two common DNA methyltransferase inhibitors (DNMTis) used in cancer treatment.
  • PLGA nanoparticles, liposomes, and gold nanoparticles are among the 11 types of nanoformulations explored for DNMTi delivery.
  • The researchers developed nanocarriers for precise delivery of methylation modulators and prolonged drug release.
  • The study has been peer-reviewed and published in the Yale Journal of Biology and Medicine.

Sources:

  • Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators. Yale Journal of Biology and Medicine, 2025;98(2):227-235.
  • NewsRx. Integral University Reports Findings in Cancer Gene Therapy (Nanotechnology-driven Epigenetic Cancer Therapy: Precision Delivery and Sustained Release of DNA Methylation Modulators). Nanotechnology Weekly. July 14, 2025; p 508.